Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD.
Transplantation. 2019 Nov;103(11):2383-2387. doi: 10.1097/TP.0000000000002596.
Recipients of nonkidney solid organ transplants (nkSOT) are living longer, and 11%-18% will develop end stage renal disease (ESRD). While our general inclination is to treat nkSOT recipients who develop ESRD with a kidney transplant (KT), an increasing number are developing ESRD at an older age where KT may not be the most appropriate treatment. It is possible that the risk of older age and prior nkSOT might synergize to make KT too risky, but this has never been explored.
To examine death-censored graft loss and mortality for KT recipients with and without prior nkSOT, we used Scientific Registry of Transplant Recipients data to identify 42 089 older (age ≥65) KT recipients between 1995 and 2016. Additionally, to better understand treatment options for these patients and survival benefit of KT, we identified 5023 older (age ≥65) with prior nkSOT recipients listed for subsequent KT, of whom 863 received transplants.
Compared with 41 159 older KT recipients without prior nkSOT, death-censored graft loss was similar (adjusted hazard ratio [aHR]: 1.13, 95% CI: 0.93-1.37, P = 0.2), but mortality (aHR: 1.40, 95% CI: 1.28-1.54, P < 0.001) was greater for older KT recipients with prior nkSOT. Nonetheless, in a survival benefit model (survival with versus without the transplant), among older prior nkSOT recipients, KT decreased the risk of mortality by more than half (aHR: 0.47, 95% CI: 0.42-0.54, P < 0.001).
Older prior nkSOT recipients who subsequently develop ESRD derive survival benefit from KT, but graft longevity is limited by overall survival in this population. These findings can help guide patient counseling for this challenging population.
接受非肾脏实体器官移植(nkSOT)的患者寿命延长,其中 11%-18%会发展为终末期肾病(ESRD)。尽管我们普遍倾向于对发生 ESRD 的 nkSOT 受者进行肾移植(KT)治疗,但越来越多的患者在年龄较大时发生 ESRD,此时 KT 可能不是最合适的治疗方法。年龄较大和先前的 nkSOT 可能会产生协同作用,使 KT 风险过高,但这从未被探讨过。
为了研究有和没有先前 nkSOT 的 KT 受者的无死亡原因移植物丢失和死亡率,我们使用 Scientific Registry of Transplant Recipients 数据确定了 1995 年至 2016 年间 42089 名年龄≥65 岁的 KT 受者。此外,为了更好地了解这些患者的治疗选择和 KT 的生存获益,我们确定了 5023 名年龄≥65 岁且有先前 nkSOT 记录的患者,他们随后被列入 KT 名单,其中 863 名接受了移植。
与 41159 名无先前 nkSOT 的年龄较大的 KT 受者相比,无死亡原因移植物丢失情况相似(调整后的危险比[aHR]:1.13,95%可信区间:0.93-1.37,P=0.2),但先前有 nkSOT 的年龄较大的 KT 受者的死亡率(aHR:1.40,95%可信区间:1.28-1.54,P<0.001)更高。尽管如此,在生存获益模型中(有与无移植的生存情况),在先前有 nkSOT 的年龄较大的受者中,KT 使死亡率降低了一半以上(aHR:0.47,95%可信区间:0.42-0.54,P<0.001)。
随后发生 ESRD 的年龄较大的先前有 nkSOT 的受者从 KT 中获得了生存获益,但在该人群中,移植物的长期存活受到总体生存的限制。这些发现可以帮助为这一具有挑战性的患者群体提供咨询。